Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OB1111
- Development stage
- Preclinical
- Lead developer
- Owen Biosciences
- Modality
- Peptides
01
Overview
OB1111 is a proprietary synthetic cationic lipo-oligopeptide (CLOP) and antimicrobial peptide (AMP) being developed by Owen Biosciences in collaboration with Alabama State University. It is designed as a broad-spectrum antimicrobial and antiviral agent. In preclinical studies, OB1111 has demonstrated potent antiviral activity against Herpes simplex virus type 1 (HSV-1) by inhibiting viral plaque formation, reducing viral load, and decreasing the expression of major viral glycoproteins (glycoprotein D and glycoprotein B). Additionally, OB1111 exhibits strong antibacterial, anti-biofilm, and anti-virulence activities against Gram-negative pathogens, specifically *Pseudomonas aeruginosa* (including PA14 and PAO1 strains), by deforming and disintegrating bacterial membranes.
02
Targets
gB (Human cytomegalovirus glycoprotein B)gD (HSV-2 glycoprotein D)
Beyond the preview
Go deeper on OB1111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OB1111.